| Decision |
Actions to Manage COI |
| Co-Chairs decision |
| SeroTracker funding, as under $500,000 |
Neither Co-Chair declared a COI. Investments under $500,000 do not require Leadership Group or Executive Committee approval, as per criteria outlined in Investment Note Approval Process |
| Leadership Group Meeting #4 – May 19, 2020, (before Executive Committee creation) |
| Two studies approved for funding: Canadian Blood Services and Héma Québec |
No members declared a COI. |
| Leadership Group Meeting #6 – June 9, 2020 (before Executive Committee creation) |
| Discussion of investment notes for Antenatal and CLSA studies |
No decision taken. |
| Leadership Group Meeting #7 – June 23, 2020 |
| Decisions regarding the following studies were on the agenda: Antenatal, CLSA, Indigenous communities and Statistics Canada |
Before discussion, it was decided an Executive Committee would be formed (read full decision here). In view of this recommendation, no decisions were taken on the four Investment Notes submitted for approval. Leadership Group members were asked to provide comments on the Investment Notes to the Secretariat. The Secretariat would collate these comments and circulate them without attribution to inform deliberations at the first meeting of the Executive Committee. |
| Executive Committee Meeting #1 – June 29, 2020 |
| EC approved support for four studies: Antenatal, CLSA (elderly), Indigenous communities, Statistics Canada (household survey) |
No recusals from discussion. ABSTENTION regarding antenatal study: Cate Hankins, due to an indirect conflict of interest because she has worked with one of the investigators within the last three years. |
| Executive Committee Meeting #2 – July 30 2020 |
| EC approved funding for 24 studies from the CIHR COVID-19 Rapid Research competition, based on evaluation by the CIHR proposal Assessment Group made up of members of the Secretariat. |
No members declared a COI. |
| EC approved support for four pediatric studies, two of which were not already in the CIHR-related proposals above (EnCORE, BC Child) |
RECUSAL FROM DISCUSSION & ABSTENTION: Gina Ogilvie, due to ties to UBC and the BC Centre for Disease Control, leading the BC Child study. |
| EC approved support for Phase 1 of CanPath study |
RECUSAL FROM DISCUSSION & ABSTENTION: Vivek Goel, given his role as co-chair of the CanPath Advisory Board until June 30, 2020. |
| Executive Committee Meeting #3 – August 27, 2020 |
| EC approved support for Correctional Services Investment Note |
ABSTENTION: Cate Hankins declared an indirect conflict of interest because she has worked with one of the investigators within the past three years. |
| Executive Committee Meeting #4 – October 28, 2020 |
| The EC reviewed the recommendations from an external review panel regarding its recent funding call on COVID-19 “Hot Spots”. Recommendations were unanimously accepted with no changes. |
COIs were identified from the EC members listed below. When a COI was identified, the EC member RECUSED themselves from discussion around the decision for the specific proposal.
- David Naylor
- James Talbot
- Jutta Preiksaitis
- Timothy Evans
- Gina Ogilvie
- Vivek Goel
|
| Executive Committee Meeting #5 – November 18, 2020 |
| EC unanimously endorsed the CITF Phase II Strategy and Workplan, as presented. |
No COI were declared for this meeting. |
| Executive Committee Meeting #6 – December 17, 2020 |
| EC approved funding for the final 2 remaining Hot spots studies, following the recommendations of the external reviewers. EC also approved amendments to the corrections studies. Gail Tomblin Murphy was introduced as replacing Jim Talbot on the EC. |
No COI were declared for this meeting. |
